Meridian Bioscience Inc. (NASDAQ:VIVO) will be releasing its earnings data before the market opens on Wednesday, November 8th. Analysts expect Meridian Bioscience to post earnings of $0.14 per share for the quarter.

Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 14.95 on Wednesday. The company has a market cap of $630.93 million, a PE ratio of 29.90 and a beta of 0.84. Meridian Bioscience Inc. has a 52-week low of $10.75 and a 52-week high of $18.58. The company has a 50 day moving average of $14.58 and a 200-day moving average of $14.48.

In other Meridian Bioscience news, Chairman John A. Kraeutler bought 7,000 shares of the firm’s stock in a transaction dated Thursday, August 24th. The stock was bought at an average cost of $13.67 per share, with a total value of $95,690.00. Following the completion of the transaction, the chairman now directly owns 345,230 shares in the company, valued at approximately $4,719,294.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Meridian Bioscience Inc. (VIVO) Set to Announce Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/01/meridian-bioscience-inc-vivo-set-to-announce-earnings-on-wednesday.html.

Several equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BidaskClub downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $14.00 price target on shares of Meridian Bioscience in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating and four have given a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $14.00.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Earnings History for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.